Evotec enters biology collaboration with Probiodrug

30-Nov-2012 - Evotec AG announced that it has entered into a collaboration with Probiodrug AG. Under the terms of the agreement, Evotec will setup and validate assays to support the pre-clinical and clinical development of glutaminyl cyclase (QC) inhibitors for the treatment of Alzheimer's disease. Glutaminyl ...

Probiodrug Collaborators Explain Interplay of Key Suspects in Alzheimer’s Disease

Nature paper demonstrates that toxicity in AD is induced by pyroglutamate Abeta and is tau protein dependent

04-May-2012 - Probiodrug AG announced its scientists and academics collaborators published seminal findings on the role of pyroglu Aβ in AD pathology in Nature. The new findings add to the growing body of evidence that pyroglu Aβ plays a crucial role in the initiation of AD. In addition, the research results ...

Probiodrug Further Expands Scientific Advisory Board by Appointing Prof Dr Dr hc Christian Haass

09-Jul-2010 - Probiodrug AG announced the appointment of Prof Dr Dr hc Christian Haass to the Company's Scientific Advisory Board. In his work, Prof Haass focuses on the molecular and cellular mechanisms of Alzheimer's and Parkinson's disease. In Alzheimer's disease, he has elucidated the biochemistry and ...

Probiodrug Obtains Additional US Patent for the Inhibition of the Enzyme Glutaminyl Cyclase (QC) to Treat CNS Diseases

18-Jun-2010 - Probiodrug AG announced that Probiodrug has been granted US patent no. 7,732,162 covering additional subject matters for the company's QC inhibitors by the United States Patent Office. The patent comprises the use of QC inhibitors to treat mild cognitive impairment, neurodegeneration in Down ...

Probiodrug Announces Supervisory Board Changes

Appointment of Claus Braestrup as Chairman of the Supervisory Board

16-Jun-2010 - Probiodrug AG (Probiodrug) announced that Dr Claus Braestrup, former President and CEO of H. Lundbeck A/S, has been appointed as a new member of the Supervisory Board and has been elected as its new Chairman. Claus Braestrup will take over from Dr Christoph Schroeder of TVM Capital who will be ...

US PTO granting Probiodrug a Further Medical Use Patent for the Inhibition of the Enzyme Glutaminyl Cyclase (QC)

17-Dec-2008 - Probiodrug AG announced that the United States Patent Office issued to Probiodrug the US patent no. 7,462,599 covering compounds and methods for the inhibition of the conversion of substrates of the enzyme glutaminyl cyclase (QC), which are causative for Familial Alzheimer's diseases, such as ...

Probiodrug Receives Research Grant of EUR 1.9 million

25-Jun-2008 - Probiodrug AG announced that the company has received a grant of EUR 1.9 million from the public research funding program "KMU innovativ: Biotechnology-BioChance", a funding program of the German Ministry of Education and Research (BMBF) to support innovative biotech SME's. The grant is split ...

Probiodrug Obtains Core Patent for Alzheimer Treatment in the U.S.

18-Jun-2008 - Probiodrug AG announced that the United States Patent Office issued to Probiodrug the US patent no. 7,381,537, the first patent covering broad methods of treating Alzheimer's disease using compounds that inhibit mammalian glutaminyl cyclase (QC). "We are very pleased about this patent as QC ...

Morphochem and Probiodrug collaborate in research and development of novel innovative dipeptidyl peptidase IV

DP IV inhibitors for the treatment of Anxiety and Depression

22-Nov-2004 - Morphochem AG and Probiodrug AG have entered into a research and collaboration for the development of novel small molecule therapeutics, initially focused on the inhibition of the serine protease dipeptidyl peptidase IV (DP IV) for the treatment of Anxiety and Depression. Under the multi-year ...

Osi Pharmaceuticals' Subsidary Prosidion Acquires Dipeptidyl Peptidase IV Platform From Probiodrug AG

Includes Phase II Development Candidate P93/01

22-Jun-2004 - Melville, Oxford, Halle (Saale). OSI Pharmaceuticals, Inc., Prosidion Limited, a subsidiary of OSI focused on the discovery and development of diabetes and obesity therapeutics, and Probiodrug AG announced today that Prosidion has agreed to purchase a platform of Dipeptidyl Peptidase IV (DP-IV) ...